Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) released its earnings results on Friday. The company reported $0.28 EPS for the quarter, Zacks reports. Bavarian Nordic had a return on equity of 11.97% and a net margin of 24.36%.
Bavarian Nordic Stock Performance
Bavarian Nordic stock traded down $0.11 during mid-day trading on Friday, hitting $11.68. The company’s stock had a trading volume of 301 shares, compared to its average volume of 3,300. The company has a 50 day moving average of $11.48 and a 200-day moving average of $10.21. Bavarian Nordic has a one year low of $8.67 and a one year high of $12.72. The stock has a market cap of $2.78 billion, a PE ratio of 11.80 and a beta of 1.33.
About Bavarian Nordic
Bavarian Nordic is a Danish biotechnology company that develops, manufactures and markets vaccines for infectious diseases and cancer immunotherapy. Founded in 1994, the company is based in Denmark and serves markets in Europe, North America and other regions. Its best-known vaccine is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, for protection against smallpox and mpox. Bavarian Nordic also offers vaccines for diseases including rabies, tick-borne encephalitis, typhoid fever and cholera.
Read More
- Five stocks we like better than Bavarian Nordic
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
